Protalix BioTherapeutics, Inc. (DE) (PLX) earnings
PLX earnings moved a median of -2.54% by the close. Quarterly and annual PLX reports and results, each read against the price at its own news timestamp. Back to the PLX overview →
30 measured PLX earnings events.
Where these PLX earnings landedvs 28 measured PLX earnings reactions
| Middle 50% of PLX earnings reactions | -6.98% to +3.58% |
|---|---|
| Median reaction (to close) | -2.54% |
| Measured reactions | 28 |
Point-in-time · zero look-ahead
Half of the 28 PLX earnings events with a measured close landed between -6.98% and +3.58%; 36% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Protalix BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | -1.21% | +5.22% | |
| Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results | Press release | -1.21% | +5.22% | |
| Protalix BioTherapeutics to Announce Second Quarter 2026 Financial Results and Business Update on August 12, 2026 | Press release | +0.00% | +2.09% | |
| Form 10-Q Protalix BioTherapeutics For: Mar 31 | SEC filing · Form 10-Q | +7.11% | -2.03% | |
| Protalix BioTherapeutics Reports First Quarter 2026 Financial and Business Results | Press release | +7.11% | -2.03% | |
| Protalix BioTherapeutics to Announce First Quarter 2026 Financial Results and Business Update on May 13, 2026 | Press release | -2.00% | +1.00% | |
| Form 10-K Protalix BioTherapeutics For: Dec 31 | SEC filing · Form 10-K | -7.49% | -3.07% | |
| Form 10-Q Protalix BioTherapeutics For: Sep 30 | SEC filing · Form 10-Q | +6.52% | — | |
| Protalix BioTherapeutics Reports Third Quarter 2025 Financial and Business Results | Press release | +6.52% | — | |
| Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 | Press release | -1.91% | -5.93% | |
| Form 10-Q Protalix BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -2.56% | |
| Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results | Press release | +0.00% | -2.56% | |
| Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 | Press release | +0.00% | -2.58% | |
| Form 10-Q Protalix BioTherapeutics For: Mar 31 | SEC filing · Form 10-Q | -17.99% | -28.03% | |
| Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results | Press release | -17.99% | -28.03% | |
| Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 | Press release | -1.83% | -5.33% | |
| Form 10-K Protalix BioTherapeutics For: Dec 31 | SEC filing · Form 10-K | +10.97% | +3.38% | |
| Form 10-Q Protalix BioTherapeutics For: Sep 30 | SEC filing · Form 10-Q | +3.17% | +11.90% | |
| Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results | Press release | +3.17% | +11.90% | |
| Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 | Press release | -1.90% | -2.52% | |
| Form 10-Q Protalix BioTherapeutics For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -10.58% | |
| Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results | Press release | +0.00% | -10.58% | |
| Protalix BioTherapeutics to Announce Second Quarter 2024 Financial and Business Results on August 14, 2024 | Press release | +0.00% | -0.99% | |
| Form 10-Q Protalix BioTherapeutics For: Mar 31 | SEC filing · Form 10-Q | +0.96% | +5.77% | |
| Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results | Press release | +0.96% | +5.77% | |
| Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024 | Press release | +0.00% | -2.56% | |
| Form 10-K Protalix BioTherapeutics For: Dec 31 | SEC filing · Form 10-K | -7.62% | -11.04% | |
| Form 10-Q Protalix BioTherapeutics For: Sep 30 | SEC filing · Form 10-Q | -0.59% | -10.12% | |
| Protalix BioTherapeutics Reports Third Quarter 2023 Financial and Business Results | Press release | -0.59% | -10.12% | |
| Protalix BioTherapeutics to Announce Third Quarter 2023 Financial and Business Results on November 6, 2023 | Press release | +0.70% | +4.20% |
Keep exploring
More PLX: analyst actions → · SEC filings → · PLX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | 198 | -0.18% | 44% |
| Inogen, Inc (INGN) | 197 | +0.31% | 60% |
| AC Immune SA (ACIU) | 195 | -0.43% | 42% |
| Stereotaxis, Inc. (STXS) | 195 | +0.23% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.